CVRX

CVRx Inc

0.8687

Nov 06 • 3:59 PM ET -0.6013 (-40.90%)

0.9498

Aftermarket • 7:30 PM ET +0.0811 (9.34%)

Healthcare Medical Devices USA Nano NASD

Nov 06, 4:47 PMCVRx cuts 2026 revenue guidance as Medicare Advantage reimbursement delays pressure growth

Peers: INSP NYXH LIVN NPCE ECOR IRTC BSX MDT BWAY SNWV

| Held by: VTI VXF IWM VTWO IWO IWC BUSM VTWG BTEC RSSL

Scroll to Statements

Index	RUT
Market Cap	24.74M
Enterprise Value	25.37M
Income	-53.26M
Sales	60.33M
Book/sh	0.49
Cash/sh	2.06
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	223
IPO	Jun 30, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	0.41
P/B	1.79
P/C	0.42
P/FCF	-
EV/EBITDA	-
EV/Sales	0.42
Quick Ratio	5.71
Current Ratio	6.80
Debt/Eq	4.30
LT Debt/Eq	4.27
Option/Short	Yes / Yes

EPS (ttm)	-2.00
EPS next Y	-1.89
EPS next Q	-0.51
EPS this Y	-0.55%
EPS next Y	7.90%
EPS next 5Y	8.64%
EPS past 3/5Y	-0.43% -22.44%
Sales past 3/5Y	36.11% 56.40%
EPS Y/Y TTM	6.12%
Sales Y/Y TTM	7.79%
EPS Q/Q	-5.69%
Sales Q/Q	-5.84%
Earnings	Nov 05 AMC
EPS/Sales Surpr.	-4.92% -0.72%

Insider Own	39.19%
Insider Trans	0.22%
Inst Own	32.23%
Inst Trans	3.33%
ROA	-53.55%
ROE	-172.17%
ROIC	-73.14%
Gross Margin	85.54%
Oper. Margin	-81.90%
Profit Margin	-88.28%
SMA20	-36.91%
SMA50	-58.30%
SMA200	-83.21%
Trades

Shs Outstand	28.49M
Shs Float	17.32M
Short Float	12.34%
Short Ratio	2.22
Short Interest	2.14M
52W High	10.63 -91.83%
52W Low	1.25 -30.78%
Volatility	20.66% 11.64%
ATR (14)	0.19
RSI (14)	24.84
Beta	0.74
Rel Volume	5.61
Avg Volume	962.16K
Volume	5,396,542

Perf Week	-38.39%
Perf Month	-48.29%
Perf Quarter	-63.35%
Perf Half Y	-87.28%
Perf YTD	-87.76%
Perf Year	-91.36%
Perf 3Y	-94.88%
Perf 5Y	-95.33%
Perf 10Y	-
Recom	3.00
Target Price	2.65
Prev Close	1.47
Price	0.87
Change %	-40.90%

Consensus

Hold

Avg. Price Target

$2.65

Implied Upside

+205.1%

Analysts7incl. previous ratings

Rating Distribution1 Buy · 5 Hold · 1 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Nov 06, 2026	Downgrade	WWilliam Blair	Outperform → Mkt Perform
Nov 06, 2026	Downgrade	CCanaccord Genuity	Buy → Hold	$2	+130.2%
Aug 07, 2026	Downgrade	PPiper Sandler	Overweight → Neutral	$4	+360.5%
Aug 07, 2026	Downgrade	LLake Street	Buy → Hold	$3.50	+302.9%
Aug 07, 2026	Downgrade	CCraig Hallum	Buy → Hold	$4	+360.5%
May 09, 2025	Downgrade	JJP Morgan	Neutral → Underweight	$7	+705.8%
Jan 14, 2025	Upgrade	WWilliam Blair	Mkt Perform → Outperform
Sep 10, 2024	Initiated	CCantor Fitzgerald	Overweight	$14	+1,511.6%
Jul 11, 2024	Reiterated	LLake Street	Buy	$18 → $12	+1,281.4%
May 01, 2024	Resumed	CCraig Hallum	Buy	$30 → $23	+2,547.6%
May 01, 2024	Downgrade	WWilliam Blair	Outperform → Mkt Perform
May 01, 2024	Downgrade	JJP Morgan	Overweight → Neutral	$36 → $13	+1,396.5%
Jan 31, 2023	Initiated	LLake Street	Buy	$20	+2,202.3%
Jul 18, 2022	Initiated	CCraig Hallum	Buy	$15	+1,626.7%
Jul 26, 2021	Initiated	WWilliam Blair	Outperform
Jul 26, 2021	Initiated	PPiper Sandler	Overweight	$26	+2,893.0%
Jul 26, 2021	Initiated	CCanaccord Genuity	Buy	$30	+3,353.4%

Nov-05-26 08:49PM	CVRx Cuts Guidance Again As Payer Friction Pushes Growth Into Reverse And Implied Q4 Plunges (Earnings Whispers) -6.96% -40.90%
05:47PM	CVRx: Q3 Earnings Snapshot (Associated Press)
04:05PM	CVRx Reports Third Quarter 2026 Financial and Operating Results (GlobeNewswire)
Nov-02-26 04:01PM	CVRx to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-28-26 07:28PM	CVRx Faces A Credibility Test As Sales-Force Repairs Meet A Lowered Revenue Bar (Earnings Whispers)
04:30PM	Loading…
Oct-22-26 04:30PM	CVRx to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call on November 5, 2026 (GlobeNewswire)
Sep-29-26 04:30PM	CVRx Announces Late-Breaking Data and New Clinical Evidence on Barostim at the HFSA Annual Scientific Meeting 2026 (GlobeNewswire) -33.46%
Sep-21-26 04:07PM	CVRx Appoints John Landry as Chief Financial Officer (GlobeNewswire)
Aug-25-26 08:00AM	CVRx Responds to Letter from Pointillist Family Office (GlobeNewswire) +6.98%
Aug-24-26 11:21AM	CVRx, Inc. Investors Who Suffered Losses Should Contact Block & Leviton LLP (Newsfile) +10.92%
08:30AM	Jorey Chernett, Owner of More than 5.5% of Outstanding Shares of CVRx, Calls on Board to Begin Immediate Process to Pursue Sale of the Company to a Strategic Acquirer (PR Newswire)
08:30AM	CVRx Announces Devoted Health Medicare Advantage Coverage Policy for Barostim Therapy (GlobeNewswire)
Aug-11-26 07:00AM	CVRx Announces Sales Leadership Transition (GlobeNewswire) +9.70%
Aug-07-26 08:24PM	CVRx, Inc. (CVRX) Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel Following Revenue Guidance Cut and Sales-Execution Disclosures (Newsfile) -59.76%
01:08AM	CVRx Inc (CVRX) (Q2 2026) Earnings Call Highlights: Sales Execution Challenges Offset Strong ... (GuruFocus.com)
06:07PM	Loading…
Aug-06-26 06:07PM	CVRx: Q2 Earnings Snapshot (Associated Press) +6.45%
04:05PM	CVRx Reports Second Quarter 2026 Financial and Operating Results (GlobeNewswire)
Aug-05-26 09:43AM	Earnings To Watch: CVRx Inc (CVRX) Q2 2026 -- GF Value Sees 142% Upside (GuruFocus.com)
Jul-28-26 08:30AM	CVRx to Present at Canaccord Genuity's 46th Annual Growth Conference (GlobeNewswire)
Jul-23-26 04:30PM	CVRx to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call on August 6, 2026 (GlobeNewswire)
Jun-09-26 07:30AM	CVRx Announces Chief Financial Officer Transition (GlobeNewswire)
May-27-26 04:30PM	CVRx to Present at the Goldman Sachs 47th Annual Global Healthcare Conference (GlobeNewswire)
May-20-26 04:30PM	CVRx to Present at the William Blair 46th Annual Growth Stock Conference (GlobeNewswire)
May-14-26 08:00AM	CVRx Announces Humana Medicare Advantage Coverage Policy for Barostim Therapy (GlobeNewswire) +9.96%
May-12-26 03:06AM	CVRx Inc (CVRX) Q1 2026 Earnings Call Highlights: Strong U.S. Growth and Market Expansion Potential (GuruFocus.com) -23.84%
May-11-26 04:50PM	CVRx: Q1 Earnings Snapshot (Associated Press)
04:05PM	CVRx Reports First Quarter 2026 Financial and Operating Results (GlobeNewswire)
May-08-26 09:18AM	CVRx Inc (CVRX) Q1 2026 Earnings Report Preview: What To Look For (GuruFocus.com) -6.69%
May-04-26 04:30PM	CVRx Announces First Patient Enrollment in BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population (GlobeNewswire)
Apr-27-26 04:30PM	CVRx to Report First Quarter 2026 Financial and Operating Results and Host Conference Call on May 11, 2026 (GlobeNewswire)
04:30PM	Loading…
Apr-20-26 04:30PM	CVRx Announces Nomination of Michael Dale for Election to the Board of Directors (GlobeNewswire)
Apr-13-26 08:00AM	CVRx Reports Preliminary First Quarter 2026 Financial Results (GlobeNewswire) +9.15%
Mar-02-26 08:30AM	CVRx Announces Late-Breaking Data and Scientific Presentations Highlighting Barostim Outcomes at the THT 2026 Annual Meeting (GlobeNewswire)
Feb-15-26 08:01PM	CVRx Inc (CVRX) Q4 2025 Earnings Call Highlights: Revenue Growth and Strategic Expansions Amid ... (GuruFocus.com)
Feb-12-26 06:19PM	CVRx Q4 Earnings Call Highlights (MarketBeat) -6.41% -13.01%
05:30PM	CVRx (CVRX) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:28PM	CVRx: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	CVRx Reports Fourth Quarter and Full Year 2025 Financial and Operating Results (GlobeNewswire)
Feb-11-26 07:35AM	What To Expect From CVRx Inc (CVRX) Q4 2025 Earnings (GuruFocus.com) -9.12%
Jan-29-26 04:10PM	CVRx to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call on February 12, 2026 (GlobeNewswire)
Jan-23-26 12:33PM	CVRx Kicks Off One Of The Largest Heart Device Trials In History (Benzinga) +11.43%
Jan-22-26 04:05PM	CVRx Announces Initiation of BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population (GlobeNewswire) +8.61%
Jan-12-26 08:00AM	CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2025 Financial Results and Issues Fiscal 2026 Guidance (GlobeNewswire) -9.86%
Jan-06-26 08:30AM	CVRx Announces Implementation of New Category I CPT Codes for Barostim Therapy (GlobeNewswire)
Dec-22-25 08:30AM	CVRx to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-19-25 08:30AM	CVRx to Participate at the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-06-25 12:03AM	CVRx Inc (CVRX) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Strategic Expansions (GuruFocus.com)
Nov-05-25 07:10PM	CVRx (CVRX) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
06:06PM	CVRx: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	CVRx Reports Third Quarter 2025 Financial and Operating Results (GlobeNewswire)
Nov-04-25 08:37AM	Earnings To Watch: CVRx Inc (CVRX) Reports Q3 2025 Result (GuruFocus.com)
08:30AM	CVRx to Present at the Jefferies Global Healthcare Conference in London (GlobeNewswire)
Oct-22-25 04:30PM	CVRx to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call on Nov. 5, 2025 (GlobeNewswire)
Aug-05-25 03:04AM	CVRx Inc (CVRX) Q2 2025 Earnings Call Highlights: Revenue Growth Amidst Strategic Expansion and ... (GuruFocus.com) -9.87%
Aug-04-25 05:20PM	CVRx (CVRX) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
04:16PM	CVRx: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	CVRx Reports Second Quarter 2025 Financial and Operating Results (GlobeNewswire)
Jul-30-25 10:00AM	Steris (STE) Earnings Expected to Grow: Should You Buy? (Zacks)
Jul-29-25 08:30AM	CVRx to Present at the Canaccord Genuity 45th Annual Growth Conference (GlobeNewswire)
Jul-28-25 10:00AM	CVRx (CVRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Jul-21-25 04:30PM	CVRx to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call on August 4, 2025 (GlobeNewswire)
Jul-17-25 04:58AM	CVRx (CVRX) Surges 19.0%: Is This an Indication of Further Gains? (Zacks)
Jul-16-25 07:30AM	CVRx Announces Positive News on Outpatient Payment for Barostim (GlobeNewswire) +19.01%
May-28-25 04:30PM	CVRx to Present at the William Blair 45th Annual Growth Stock Conference (GlobeNewswire)
May-09-25 03:40AM	CVRx Inc (CVRX) Q1 2025 Earnings Call Highlights: Revenue Growth Amid Sales Force Realignment ... (GuruFocus.com) -38.69%
May-08-25 06:35PM	CVRx (CVRX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
05:27PM	CVRx: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	CVRx Reports First Quarter 2025 Financial and Operating Results (GlobeNewswire)
May-07-25 11:20AM	What To Expect From CVRx Inc (CVRX) Q1 2025 Earnings (GuruFocus.com)
May-06-25 10:00AM	908 Devices Inc. (MASS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
May-01-25 10:01AM	CVRx (CVRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Apr-24-25 04:30PM	CVRx to Report First Quarter 2025 Financial and Operating Results and Host Conference Call on May 8, 2025 (GlobeNewswire) +6.06%
Apr-09-25 08:45AM	CVRx Inc: Overreaction Creates Buying Opportunity (Seeking Alpha) +17.26%
Apr-07-25 04:05PM	CVRx Reports Preliminary First Quarter 2025 Financial Results (GlobeNewswire) -46.27%
Feb-12-25 02:45PM	CVRx announces new real-world evidence demonstrating significant reductions in healthcare utilization with Barostim (GlobeNewswire)
Feb-11-25 09:55AM	CVRx (CVRX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
Feb-07-25 09:55AM	Wall Street Analysts Predict a 25.76% Upside in CVRx (CVRX): Here's What You Should Know (Zacks)
Feb-05-25 02:14AM	CVRx Inc (CVRX) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amidst Rising Expenses (GuruFocus.com) -7.20%
Feb-04-25 05:45PM	CVRx (CVRX) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +5.11%
04:49PM	CVRx: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	CVRx Reports Fourth Quarter and Full Year 2024 Financial and Operating Results (GlobeNewswire)
Feb-03-25 07:08AM	CVRx Inc (CVRX) Q4 2024 Earnings Report Preview: What To Expect (GuruFocus.com)
Jan-21-25 04:30PM	CVRx to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call on February 4, 2025 (GlobeNewswire) -6.47%
Jan-16-25 10:00AM	CVRx (CVRX) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Jan-13-25 08:00AM	CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2024 Financial Results and Issues Fiscal 2025 Guidance (GlobeNewswire) +6.14%
Dec-23-24 04:30PM	CVRx to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-26-24 08:31AM	Cvrx (CVRX) Declined Due To Turbulence In The Direct Sales Team (Insider Monkey)
Nov-20-24 04:30PM	CVRx to Present at the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire) +9.25%
Nov-04-24 08:00AM	CVRx Announces Positive Outpatient Payment for Barostim Procedure in 2025 (GlobeNewswire) +12.31%
Oct-30-24 03:14AM	CVRx Inc (CVRX) Q3 2024 Earnings Call Highlights: Revenue Surge Amid Rising Expenses (GuruFocus.com) +31.01%
Oct-29-24 05:50PM	CVRx (CVRX) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:46PM	CVRx: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	CVRx Reports Third Quarter 2024 Financial and Operating Results (GlobeNewswire)
Oct-28-24 09:08AM	Earnings To Watch: CVRx Inc (CVRX) Reports Q3 2024 Result (GuruFocus.com)
Oct-21-24 08:42AM	CVRx (CVRX) Soars 17.2%: Is Further Upside Left in the Stock? (Zacks) +8.11%
06:40AM	CVRx announces new CPT Category I codes for Barostim heart failure therapy (Medical Device Network)
Oct-19-24 02:10PM	CVRx announces new CPT Category I codes for Barostim (TipRanks)
Oct-18-24 02:08PM	CVRx announces new CPT Category I codes for Barostim (GlobeNewswire) +17.16%
Oct-15-24 04:30PM	CVRx to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call on October 29, 2024 (GlobeNewswire)
Sep-12-24 10:13AM	CVRx touts positive two-year data for heart failure neuromodulation device (Medical Device Network) -6.17%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Binkowski Brent	CHIEF OPERATING OFFICER	Aug 13 '26	Buy	2.91	26,223	76,432	56,514	Aug 13 08:18 PM
Binkowski Brent	CHIEF OPERATING OFFICER	Aug 12 '26	Sale	2.55	1,309	3,338	30,291	Aug 13 04:26 PM
Adamson Philip B.	Chief Medical Officer	Mar 02 '26	Sale	7.90	1,262	9,973	61,578	Mar 16 04:16 PM
Hykes Kevin	PRES & CEO	Mar 02 '26	Sale	7.90	7,763	61,349	284,237	Mar 03 06:03 PM
VERRASTRO PAUL	CHIEF MKTG & STRAT OFFICER	Mar 02 '26	Sale	7.90	1,284	10,146	60,551	Mar 03 06:03 PM
OASHEIM JARED	CHIEF FINANCIAL OFFICER	Mar 02 '26	Sale	7.90	1,744	13,781	96,703	Mar 03 06:02 PM
John Robert Allen	Chief Revenue Officer	Mar 02 '26	Sale	7.90	3,964	31,326	86,036	Mar 03 06:01 PM
Jain Mudit K.	Director	Feb 20 '26	Buy	6.36	46,800	297,592	980,183	Feb 23 06:00 AM
Jain Mudit K.	Director	Feb 18 '26	Buy	4.64	600	2,785	5,650	Feb 18 05:22 PM
JOHNSON & JOHNSON	10% Owner	Nov 26 '25	Sale	10.03	6,337	63,560	4,040,861	Dec 01 04:07 PM
JOHNSON & JOHNSON	10% Owner	Nov 24 '25	Sale	10.06	2,200	22,132	4,047,198	Nov 25 12:54 PM
JOHNSON & JOHNSON	10% Owner	Nov 21 '25	Sale	10.00	500	5,000	4,049,398	Nov 25 12:54 PM
JOHNSON & JOHNSON	10% Owner	Nov 12 '25	Sale	10.00	1,000	10,000	4,049,898	Nov 14 03:07 PM

CVRx, Inc. engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It operates through the following geographical segments: United States, Germany, and Other Countries. The company was founded by Robert S. Kieval and Tyler P. Lipschultz in August 2001 and is headquartered in Minneapolis, MN.

PresidentMr. Kevin Hykes

M.Sc.Dr. Philip B. Adamson M.D.

Chief Financial OfficerMr. John Landry

Chief Operating OfficerMr. Brent Binkowski

Vice PresidentMr. Matt Klein

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CVRX

CVRx Inc

Upgrade your Finviz experience